• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC TO-T filed by Nuvalent Inc.

    6/24/26 7:15:02 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NUVL alert in real time by email
    SC TO-T 1 d90297dsctot.htm SC TO-T SC TO-T
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE TO

    Tender Offer Statement under Section 14(d)(1) or 13(e)(1)

    of the Securities Exchange Act of 1934

     

     

    NUVALENT, INC.

    (Name of Subject Company (Issuer))

    HARMONY ROW ACQUISITION CO.,

    GLAXOSMITHKLINE LLC

    and

    GSK PLC

    (Names of Filing Persons - Offerors)

    Class A Common Stock, par value $0.0001 per share

    Class B Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    670703107*

    (CUSIP Number of Class of Securities)

    David Rea

    GlaxoSmithKline LLC

    1250 South Collegeville Road

    Collegeville, PA 19426

    +1 215-219-7521

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)

     

     

    Copy to:

    William J. Chudd

    Daniel Brass

    Davis Polk & Wardwell LLP

    450 Lexington Avenue

    New York, New York 10017

    +1 212-450-4000

     

     

     

     

    ☐ 

    Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

    Check the appropriate boxes below to designate any transactions to which the statement relates:

     

      ☒ 

    Third-party tender offer subject to Rule 14d-1.

      ☐ 

    Going-private transaction subject to Rule 13e-3.

      ☐ 

    Third-party tender offer subject to Rule 14d-1.

      ☐ 

    Amendment to Schedule 13D under Rule 13d-2.

    Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

    If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

     

      ☐ 

    Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

      ☐ 

    Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

     

     
     

     

    *

    This CUSIP number applies to the issuer’s Class A Common Stock.


    This Tender Offer Statement on Schedule TO (together with any amendments and supplements hereto, this “Schedule TO”) is filed by (i) GSK plc, a public limited company organized under the laws of England and Wales (“Ultimate Parent”), (ii) GlaxoSmithKline LLC, a Delaware limited liability company and an indirect wholly-owned subsidiary of Ultimate Parent (“Parent”), and (iii) Harmony Row Acquisition Co., a Delaware corporation (“Purchaser”) and a direct wholly-owned subsidiary of Parent. This Schedule TO relates to the offer by Purchaser to purchase all of the issued and outstanding shares of the Class A Common Stock, par value $0.0001 per share (the “Class A Shares”), and Class B Common Stock, par value $0.0001 per share (the “Class B Shares” and, together with the Class A Shares, the “Shares”), of Nuvalent, Inc., a Delaware corporation (the “Company”), for $124.00 per Share, net to the seller in cash, without interest (such consideration as it may be increased from time to time pursuant to the terms of the Merger Agreement (as defined below), the “Offer Price”), subject to any applicable withholding taxes, and upon the terms and subject to the conditions set forth in the Offer to Purchase, dated June 24, 2026 (together with any amendments or supplements thereto, the “Offer to Purchase”) and in the accompanying letter of transmittal (together with any amendments or supplements thereto, the “Letter of Transmittal” which, together with the Offer to Purchase and other related materials, as they may be amended or supplemented from time to time, collectively constitute the “Offer”), copies of which are annexed to and filed with this Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

    All information contained in the Offer to Purchase (including Schedule I to the Offer to Purchase) and the accompanying Letter of Transmittal is hereby expressly incorporated herein by reference in response to Items 1 through 9 and Item 11 of this Schedule TO.

    The Agreement and Plan of Merger, dated as of June 9, 2026 (as it may be amended or supplemented from time to time, the “Merger Agreement”), by and among the Company, Parent, Purchaser and solely for purposes of Section 9.14 therein, Ultimate Parent, a copy of which is attached as Exhibit (d)(1) hereto, is incorporated herein by reference with respect to Items 4 through 9 and 11 of this Schedule TO.

    Item 1. Summary Term Sheet.

    The information set forth in the “Summary Term Sheet” of the Offer to Purchase is incorporated herein by reference.

    Item 2. Subject Company Information.

    (a) The name of the subject company and the issuer of the securities to which this Schedule TO relates is Nuvalent, Inc., a Delaware corporation. The Company’s principal executive offices are located at One Broadway, 14th Floor Cambridge, MA 02142. The Company’s telephone number is (857) 357-7000.

    (b) This Schedule TO relates to the outstanding Class A Shares and Class B Shares. The Company has advised Parent, Purchaser, and Ultimate Parent that, as of the close of business on June 17, 2026, 73,899,592 Class A Shares were issued and outstanding and 5,435,254 Class B Shares were issued and outstanding.

    (c) The information concerning the principal market in which the Shares are traded, and certain high and low sales prices for Shares in the principal market in which the Shares are traded, are set forth in Section 6 (entitled “Price Range of Shares; Dividends on the Shares”) of the Offer to Purchase is incorporated herein by reference.

    Item 3. Identity and Background of the Filing Person.

    (a) - (c) This Schedule TO is filed by Purchaser, Parent and Ultimate Parent. The information set forth in Section 8 (entitled “Certain Information Concerning Ultimate Parent, Parent, Purchaser and Certain Related Persons”) of the Offer to Purchase and Schedule I to the Offer to Purchase is incorporated herein by reference.

    Item 4. Terms of the Transaction.

    The information set forth in the Offer to Purchase is incorporated herein by reference.

     

    2


    Item 5. Past Contacts, Transactions, Negotiations and Agreements.

    (a), (b) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

     

      •  

    the “Summary Term Sheet”

     

      •  

    Section 7 - “Certain Information Concerning the Company”

     

      •  

    Section 8 - “Certain Information Concerning Ultimate Parent, Parent, Purchaser and Certain Related Persons”

     

      •  

    Section 10 - “Background of the Offer; Past Contacts or Negotiations with the Company”

     

      •  

    Section 11 - “The Merger Agreement; Other Agreements”

     

      •  

    Section 12 - “Purpose of the Offer; Plans for the Company”

     

      •  

    Schedule I

    Item 6. Purposes of the Transaction and Plans or Proposals.

    (a), (c)(1) - (7) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

     

      •  

    the “Summary Term Sheet”

     

      •  

    Section 6 - “Price Range of Shares; Dividends on the Shares”

     

      •  

    Section 10 - “Background of the Offer; Past Contacts or Negotiations with the Company”

     

      •  

    Section 11 - “The Merger Agreement; Other Agreements”

     

      •  

    Section 12 - “Purpose of the Offer; Plans for the Company”

     

      •  

    Section 13 - “Certain Effects of the Offer”

     

      •  

    Schedule I

    (c)(8) and (9) Not applicable.

    Item 7. Source and Amount of Funds or Other Consideration.

    (a), (b), (d) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

     

      •  

    Section 9 - “Source and Amount of Funds”

    Item 8. Interest in Securities of the Subject Company.

    (a) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

     

      •  

    the “Summary Term Sheet”

     

      •  

    Section 8 - “Certain Information Concerning Ultimate Parent, Parent, Purchaser and Certain Related Persons”

     

      •  

    Section 11 - “The Merger Agreement; Other Agreements”

     

      •  

    Schedule I

    (b) Not applicable.

     

    3


    Item 9. Persons/Assets, Retained, Employed, Compensated or Used.

    (a) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

     

      •  

    the “Summary Term Sheet”

     

      •  

    Section 3 - “Procedures for Accepting the Offer and Tendering Shares”

     

      •  

    Section 10 - “Background of the Offer; Past Contacts or Negotiations with the Company”

     

      •  

    Section 18 - “Fees and Expenses”

    Item 10. Financial Statements.

    Not applicable. In accordance with the instructions to Item 10 of the Schedule TO, the financial statements are not considered material because:

    (a) the consideration offered consists solely of cash;

    (b) the Offer is not subject to any financing condition; and

    (c) the Offer is for all outstanding securities of the subject classes.

    Item 11. Additional Information.

    (a)(1) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

     

      •  

    Section 8 - “Certain Information Concerning Ultimate Parent, Parent, Purchaser and Certain Related Persons”

     

      •  

    Section 10 - “Background of the Offer; Past Contacts or Negotiations with the Company”

     

      •  

    Section 11 - “The Merger Agreement; Other Agreements”

     

      •  

    Section 12 - “Purpose of the Offer; Plans for the Company”

    (a)(2) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

     

      •  

    Section 12 - “Purpose of the Offer; Plans for the Company”

     

      •  

    Section 15 - “Conditions of the Offer”

     

      •  

    Section 16 - “Certain Legal Matters; Regulatory Approvals”

    (a)(3) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

     

      •  

    Section 15 - “Conditions of the Offer”

     

      •  

    Section 16 - “Certain Legal Matters; Regulatory Approvals”

    (a)(4) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

     

      •  

    Section 13 - “Certain Effects of the Offer”

    (a)(5) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

     

      •  

    Section 16 - “Certain Legal Matters; Regulatory Approvals”

     

    4


    (c) The information set forth in the Offer to Purchase and the Letter of Transmittal is incorporated herein by reference.

    Item 12. Exhibits.

     

    Exhibit No.  

    Description

    (a)(1)(A)   Offer to Purchase, dated June 24, 2026.*
    (a)(1)(B)   Form of Letter of Transmittal (including Internal Revenue Service Form W-9).*
    (a)(1)(C)   Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and other Nominees.*
    (a)(1)(D)   Form of Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and other Nominees.*
    (a)(1)(E)   Summary Advertisement as published in The Wall Street Journal on June 24, 2026.*
    (a)(5)(A)   Press Release of Ultimate Parent, dated June 9, 2026 (incorporated herein by reference to Exhibit 99(a)(5)(a) to the Schedule TO-C filed by Ultimate Parent on June 9, 2026, Film Number 261074584).
    (a)(5)(B)   Investor call slides of Ultimate Parent, dated June  9, 2026 (incorporated herein by reference to Exhibit 99(a)(5)(a) to the Schedule TO-C filed by Ultimate Parent on June 9, 2026, Film Number 261077179).
    (a)(5)(C)   Transcript of media call by Ultimate Parent (incorporated herein by reference to Exhibit 99(a)(5)(b) to the Schedule TO-C filed by Ultimate Parent on June 9, 2026, Film Number 261077179).
    (a)(5)(D)   Social media content by Ultimate Parent on X (incorporated herein by reference to Exhibit 99(a)(5)(c) to the Schedule TO-C filed by Ultimate Parent on June 9, 2026, Film Number 261077179).
    (a)(5)(E)   Social media content by Ultimate Parent on LinkedIn (incorporated herein by reference to Exhibit 99(a)(5)(d) to the Schedule TO-C filed by Ultimate Parent on June 9, 2026, Film Number 261077179).
    (a)(5)(F)   Social media content by Ultimate Parent on Bluesky (incorporated herein by reference to Exhibit 99(a)(5)(e) to the Schedule TO-C filed by Ultimate Parent on June 9, 2026, Film Number 261077179).
    (a)(5)(G)   Social media content by Tony Wood on LinkedIn (incorporated herein by reference to Exhibit 99(a)(5)(f) to the Schedule TO-C filed by Ultimate Parent on June 9, 2026, Film Number 261077179).
    (a)(5)(H)   Social media content by Chris Sheldon on LinkedIn (incorporated herein by reference to Exhibit 99(a)(5)(g) to the Schedule TO-C filed by Ultimate Parent on June 9, 2026, Film Number 261077179).
    (a)(5)(I)   Social media content by Mondher Mahjoubi on LinkedIn (incorporated herein by reference to Exhibit 99(a)(5)(a) to the Schedule TO-C filed by Ultimate Parent on June 10, 2026).
    (a)(5)(J)   Social media content by Julie Brown on LinkedIn (incorporated herein by reference to Exhibit 99(a)(5)(b) to the Schedule TO-C filed by Ultimate Parent on June 10, 2026).
    (b)(1)   Facility Agreement, dated as of June  9, 2026, by and among Parent, Bank of America, N.A., London Branch and Citibank, N.A. and its affiliates (as arrangers and original lenders), Citibank Europe plc, UK Branch (as agent) and Ultimate Parent (as guarantor).*
    (d)(1)   Agreement and Plan of Merger, dated as of June  9, 2026, by and among the Company, Parent, Purchaser and, solely as set forth in Section  9.14 therein, Ultimate Parent (incorporated herein by reference to Exhibit 2.1 to the Form 8-K filed by the Company on June 9, 2026).
    (d)(2)   Form of Tender and Support Agreement (incorporated herein by reference to Exhibit 10.1 to the Form 8-K filed by the Company on June 9, 2026).
    (d)(3)   Confidential Disclosure Agreement, dated as of September 3, 2025, by and between Parent and the Company.*
    (g)   Not applicable.
    (h)   Not applicable.
    107   Filing Fee Table.*
     
    *

    Filed herewith

     

    5


    Item 13. Information Required by Schedule 13E-3.

    Not applicable.

     

    6


    SIGNATURES

    After due inquiry and to the best knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: June 24, 2026

     

    GLAXOSMITHKLINE LLC

    By:   /s/ Justin Huang
     

    Name: 

     

    Justin Huang

     

    Title:

     

    Secretary

    HARMONY ROW ACQUISITION CO.

    By:   /s/ Justin Huang
     

    Name:

     

    Justin Huang

     

    Title:

     

    President and Secretary

    GSK PLC

    By:   /s/ David Redfern
     

    Name:

     

    David Redfern

     

    Title:

     

    Authorized Signatory

     

    7

    Get the next $NUVL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUVL

    DatePrice TargetRatingAnalyst
    6/24/2026$124.00Outperform → Mkt Perform
    Bernstein
    5/22/2026$189.00Outperform
    Bernstein
    3/30/2026$116.00Overweight
    Wells Fargo
    11/24/2025Buy
    Truist
    11/12/2025$126.00Buy
    Canaccord Genuity
    10/16/2025$115.00Buy
    Stifel
    10/15/2025$135.00Overweight
    Cantor Fitzgerald
    9/4/2025$122.00Buy
    Guggenheim
    More analyst ratings

    $NUVL
    SEC Filings

    View All

    SEC Form SC 14D9 filed by Nuvalent Inc.

    SC 14D9 - Nuvalent, Inc. (0001861560) (Subject)

    6/24/26 8:02:34 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC TO-T filed by Nuvalent Inc.

    SC TO-T - Nuvalent, Inc. (0001861560) (Subject)

    6/24/26 7:15:02 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Nuvalent, Inc. (0001861560) (Filer)

    6/18/26 4:30:29 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director by Deputization Flynn James E was granted 3,444 shares (SEC Form 4)

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    6/18/26 6:35:22 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wheeler Cameron was granted 3,444 shares, increasing direct ownership by 67% to 8,590 units (SEC Form 4)

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    6/18/26 4:35:56 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Srivastava Sapna was granted 3,444 shares, increasing direct ownership by 67% to 8,590 units (SEC Form 4)

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    6/18/26 4:35:20 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nuvalent downgraded by Bernstein with a new price target

    Bernstein downgraded Nuvalent from Outperform to Mkt Perform and set a new price target of $124.00

    6/24/26 8:38:37 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Nuvalent with a new price target

    Bernstein initiated coverage of Nuvalent with a rating of Outperform and set a new price target of $189.00

    5/22/26 9:02:44 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Nuvalent with a new price target

    Wells Fargo initiated coverage of Nuvalent with a rating of Overweight and set a new price target of $116.00

    3/30/26 8:25:33 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation Accelerates

    DENVER, June 09, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade. One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research an

    6/9/26 9:44:01 AM ET
    $GSK
    $NUVL
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC

    New Drug Application for neladalkib in TKI pre-treated advanced ALK-positive NSCLC accepted for filing with Priority Review by the FDA with PDUFA target action date of November 27, 2026Veteran biopharmaceutical executive, Georg Pirmin Meyer, M.D., joins as Chief International Officer to lead Nuvalent's global expansion strategyCAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the acceptance of its New Drug Application (NDA) for neladalkib for filing by the U.S. Food and Drug Administration (FDA). The FDA has gra

    5/27/26 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting

    Presentation of pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from ALKOVE-1 trialTKI pre-treated data from ALKOVE-1 trial of neladalkib support recent NDA submission and ongoing investigation in Phase 3 ALKAZAR trial for TKI-naïve patients with advanced ALK-positive NSCLCFirst presentation of encouraging preliminary data for zidesamtinib in patients with advanced ROS1-positive solid tumors other than NSCLC from ARROS-1 trialCAMBRIDGE, Mass., May 21, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highli

    5/21/26 5:23:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Leadership Updates

    Live Leadership Updates

    View All

    Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC

    New Drug Application for neladalkib in TKI pre-treated advanced ALK-positive NSCLC accepted for filing with Priority Review by the FDA with PDUFA target action date of November 27, 2026Veteran biopharmaceutical executive, Georg Pirmin Meyer, M.D., joins as Chief International Officer to lead Nuvalent's global expansion strategyCAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the acceptance of its New Drug Application (NDA) for neladalkib for filing by the U.S. Food and Drug Administration (FDA). The FDA has gra

    5/27/26 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Appoints Ron Squarer to Board of Directors

    CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron Squarer to its Board of Directors. "We welcome Ron to our Board of Directors, where his personal dedication to advancing oncology therapeutics, demonstrated success in evolving research and development organizations to fully integrated businesses, and proven global commercial acumen will strengthen and sharpen our pre-launch

    12/10/25 4:01:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

    Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025 Initiated ALKAZAR Phase 3 randomized, controlled trial of neladalkib for front-line ALK-positive NSCLC Topline pivotal data for neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC expected by year-end 2025 Preliminary data for neladalkib in patients with ALK-positive solid tumors beyond NSCLC to be presented at the ESMO Congress 2025 Jason Waters, MBA, promoted to Senior Vice President, Commercial CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical

    8/7/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Financials

    Live finance-specific insights

    View All

    Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

    In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks, respectivelyIn the subset of 63 TKI pre-treated patients who were lorlatinib-naïve, ORR by BICR was 46% (95% CI: 33, 59), with initial estimated durability of response of 80% and 60% at the 12- and 18-month landmarks, respectivelyNeladalkib demonstrated intracranial responses, ability to address key drivers of disease progression, and a generally well-tolerated safety profile with low rates of dose discontinuation (5%) and dose reduction (17%) due to TEAEs, consistent with its ALK-selective, TRK-sparing designCompany p

    11/17/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib

    Company to host webcast and conference call on November 17, 2025 at 8:00am ET CAMBRIDGE, Mass., Nov. 14, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the company will host a webcast and conference call on Monday, November 17, 2025 at 8:00 a.m. ET, to discuss topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 Phase 1/2 clinical trial.

    11/14/25 4:01:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

    Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the company plans to initiate a rolling NDA submission in July 2025 with target completion in the third quarter of 2025In 117 ROS1 TKI pre-treated patients, including 50% who had received ≥ 2 prior ROS1 TKIs ± chemotherapy, ORR by BICR was 44% (95% CI: 34, 53) with initial estimated durability of response of 78% at the 12-month landmark and 62% at the 18-month landmarkIn the subset of 55 patients treated with 1 prior ROS1 TKI (crizotinib or entrectinib) ± chemotherapy, ORR was 51% (95% CI: 37, 65) with initial estimated durability of respo

    6/24/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nuvalent Inc.

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    11/14/24 4:50:28 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nuvalent Inc.

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    11/14/24 4:34:36 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nuvalent Inc. (Amendment)

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    5/15/24 6:39:30 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care